The ADVANTAGE Seeding Trial: A Review of Internal Documents
- 19 August 2008
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (4), 251-258
- https://doi.org/10.7326/0003-4819-149-4-200808190-00006
Abstract
Seeding trials, clinical studies conducted by pharmaceutical companies that are designed to seem as if they answer a scientific question but primarily fulfill marketing objectives, have not been described in detail. To describe a known seeding trial, ADVANTAGE (Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness), through documents of the trial sponsor, Merck & Co. (Whitehouse Station, New Jersey). Merck internal and external correspondence, reports, and presentations elicited to inform legal proceedings of Cona v Merck and Co., Inc., and McDarby v Merck and Co., Inc. The documents were created between 1998 and 2006. An iterative case-study process of review, discussion, and re-review of documents to identify themes relevant to the design and conduct of ADVANTAGE. To supplement the case-study review, the authors did a systematic review of the literature to identify published manuscripts focused on seeding trials and their conduct. Review of the documents revealed 3 key themes: The trial was designed by Merck's marketing division to fulfill a marketing objective; Merck's marketing division handled both the scientific and the marketing data, including collection, analysis, and dissemination; and Merck hid the marketing nature of the trial from participants, physician investigators, and institutional review board members. Although the systematic review of the literature identified 6 articles that focused on the practice of seeding trials, none provided documentary evidence of their existence or conduct. The legal documents in these cases provide useful, but limited, information about the practices of the pharmaceutical industry. This description of 1 company's actions is incomplete and may have limited generalizability. Documentary evidence shows that ADVANTAGE is an example of marketing framed as science. The documents indicate that ADVANTAGE was a seeding trial developed by Merck's marketing division to promote prescription of Vioxx (rofecoxib) when it became available on the market in 1999.Keywords
This publication has 10 references indexed in Scilit:
- Critical Lessons From the ENHANCE TrialPublished by American Medical Association (AMA) ,2008
- What have we learnt from Vioxx?BMJ, 2007
- The Role of Litigation in Defining Drug RisksPublished by American Medical Association (AMA) ,2007
- Faculty Opinions recommendation of Narrative review: the promotion of gabapentin: an analysis of internal industry documents.Published by H1 Connect ,2006
- How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug PreferencesJAMA, 2006
- Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertisingTobacco Control, 2006
- International variation in prescribing antihypertensive drugs: Its extent and possible explanationsBMC Health Services Research, 2005
- How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93Tobacco Control, 2002
- Therapeutic-Class Wars -- Drug Promotion in a Competitive MarketplaceNew England Journal of Medicine, 1994
- Marketing Aspects of Company-Sponsored Postmarketing Surveillance StudiesDrug Safety, 1993